<i>EGFR</i>-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib-Reference-Cited by-同舟云学术

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib

Published:2018 Issue:7 Volume:57 Page:1007-1010
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kobayashi Keigo¹,Naoki Katsuhiko¹²,Kuroda Aoi¹,Yasuda Hiroyuki¹,Kawada Ichiro¹,Soejima Kenzo¹³,Betsuyaku Tomoko¹

Affiliation:

1. Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan

2. Cancer Center, Keio University School of Medicine, Japan

3. Clinical and Translational Research Center, Keio University School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/57/7/57_9609-17/_pdf

Reference8 articles.

1. 1. Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35: 1288-1296, 2017.

2. 2. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372: 1689-1699, 2015.

3. 3. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003.

4. 4. Tani T, Naoki K, Asakura T, et al. Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report. Mol Clin Oncol 5: 488-490, 2016.

5. 5. Noonan SA, Sachs PB, Camidge DR, et al. Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11: 2253-2258, 2016.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101);Targeted Oncology;2024-04-13

2. Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report;Case Reports in Oncology;2023-03-28

3. TAPO in first‐line osimertinib therapy and continuation of osimertinib;Thoracic Cancer;2022-12-28

4. A Study of the Relationship Between Interstitial Lung Abnormalities and Osimertinib-induced Lung Injury;Haigan;2022-08-20

5. Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis;Case Reports in Oncology;2021-05-26